A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Go Back to All Clinical Trials

A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Brief description of study

The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment for advanced or metastatic solid tumors with a proven ALK, ROS or NTRK 1-3 gene rearrangement. An investigational medication or drug is one that has not been approved by the U.S. Food & Drug Administration (FDA).

Clinical Study Identifier: s19-00440

ClinicalTrials.gov Identifier: NCT03093116

Principal Investigator: Vamsidhar Velcheti.

Other Investigators: Salman Rafi Punekar, Elaine Shum, Sally Lau, Joshua K Sabari, David Mendoza, Melissa L Martinez, Natalia Cherkassky.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies